This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/mesh/concept/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/chemspider/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n12http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n18http://www.drugs.com/mtm/
n26http://www.rxlist.com/cgi/generic/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/bindingdb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/pubchem-compound/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/kegg-drug/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/pubchem-substance/
n6http://linked.opendata.cz/resource/drugbank/property/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/iuphar/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00342/identifier/guide-to-pharmacology/

Statements

Subject Item
n2:DB00342
rdf:type
n5:Drug
n5:description
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
n5:group
withdrawn
n5:halfLife
3.5 hours
n5:indication
For the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
owl:sameAs
n12:DB00342 n15:DB00342
dcterms:title
Terfenadine
adms:identifier
n4:50017376 n7:PA451619 n10:Terfenadine n19:2608 n20:5212 n21:DB00342 n22:D00521 n23:5405 n24:2608 n25:C07463 n27:46507007
n5:mechanismOfAction
Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal.
n5:packager
n16:271B5ADE-363D-11E5-9242-09173F13E4C5 n16:271B5ADF-363D-11E5-9242-09173F13E4C5 n16:271B5ADD-363D-11E5-9242-09173F13E4C5
n5:synonym
Terfenadin (RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol Terfenadine Terfenadina Terfenadinum Terfénadine
n5:toxicity
Mild (e.g., headache, nausea, confusion), but adverse cardiac events including cardiac arrest, ventricular arrhythmias including torsades de pointes and QT prolongation have been reported. LD<sub>50</sub>=mg/kg (orally in mice)
n5:mixture
n13:271B5AD9-363D-11E5-9242-09173F13E4C5 n13:271B5ADA-363D-11E5-9242-09173F13E4C5 n13:271B5ADB-363D-11E5-9242-09173F13E4C5 n13:271B5ADC-363D-11E5-9242-09173F13E4C5
n5:proteinBinding
70%
n5:synthesisReference
Timothy G. Fawcett, Christian T. Goralski, David W. Ziettlow, "Preparation of polymorphically pure terfenadine." U.S. Patent US4742175, issued April, 1975.
n8:hasConcept
n9:M0025307
foaf:page
n18:terfenadine.html n26:terfen.htm
n5:IUPAC-Name
n6:271B5AE4-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5AEA-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5AE9-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5AE6-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5AE7-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5AE8-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5AFA-363D-11E5-9242-09173F13E4C5 n6:271B5AE2-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5AFC-363D-11E5-9242-09173F13E4C5 n6:271B5AE3-363D-11E5-9242-09173F13E4C5 n6:271B5AE0-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5AE1-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B5AF0-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5AF1-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5AEB-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5AEC-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5AEE-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5AED-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5AEF-363D-11E5-9242-09173F13E4C5
n5:absorption
On the basis of a mass balance study using 14C labeled terfenadine the oral absorption of terfenadine was estimated to be at least 70%
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
50679-08-8
n5:category
n5:Bioavailability
n6:271B5AF6-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5AF8-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5AF9-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5AFB-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5AF5-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5AF4-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5AF7-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5AE5-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5AF2-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5AF3-363D-11E5-9242-09173F13E4C5